Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline
Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline
复制标题
DOI：
10.1016/j.febslet.2013.09.017
复制
发表时间：
2013-11-15
期刊：
影响因子：
3.5
通讯作者：
Simizu, Siro
中科院分区：
文献类型：
--
作者：
Kuroda, Masahiro;Funasaki, Shintaro;Simizu, Siro
Conophylline（CNP）具有多种生物活性，如产生胰岛素。最近的一项研究确定ADP-核糖基化因子样6相互作用蛋白1（ARL 6 ip 1）为CNP的直接靶蛋白。在本研究中，我们揭示了ARL 6 ip 1是一个三跨膜蛋白，并确定了CNP-binding域的ARL 6 ip 1的缺失突变与生物素-氨基-CNP。这些结果表明，CNP有望用于未来ARL 6 ip 1在细胞中功能的研究。由于ARL 6 ip 1的抗凋亡功能，CNP可能是人类癌症和其他疾病的有效治疗药物和/或新型化疗增敏剂。(C)2013年欧洲生物化学学会联合会。Elsevier B. V.出版，保留所有权利。
Conophylline (CNP) has various biological activities, such as insulin production. A recent study identified ADP-ribosylation factor-like 6-interacting protein 1 (ARL6ip1) as a direct target protein of CNP. In this study, we revealed that ARL6ip1 is a three-spanning transmembrane protein and determined the CNP-binding domain of ARL6ip1 by deletion mutation analysis of ARL6ip1 with biotinyl-amino-CNP. These results suggest that CNP is expected to be useful for future investigation of ARL6ip1 function in cells. Because of the anti-apoptotic function of ARL6ip1, CNP may be an effective therapeutic drug and/or a novel chemosensitizer for human cancers and other diseases. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.